|
Amarin Corporation plc ("Amarin" or "the Company") is a neuroscience company focused on the research, development, and commercialization of novel drugs to treat central nervous system (CNS) disorders, with a particular emphasis on neurological diseases and disorders. The Company’s most advanced product, Miraxion™, is in Phase III development for Huntington's disease (HD) and in Phase II for depressive disorders. The Company is using a proprietary technology platform based on an understanding of the chemical nature of the brain. Amarin’s lipophilic drugs are predominantly fat-soluble and thus can easily cross the blood-brain barrier into the brain, conferring many advantages over traditional treatments. HD is a lethal, autosomal dominant, genetic disease, characterized by severe movement disorder, dementia, and psychiatric disturbance. There is currently no approved treatment for this disease in the U.S. Miraxion™ has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for HD and has received Orphan Drug Status in the U.S. and Europe. Depression is one of the most common mental illnesses, affecting more than 19 million people in the U.S. and representing a $14 billion market dominated by selective serotonin reuptake inhibitors (SSRIs). About one-third of depressed patients fail to respond to standard drugs and another third show only partial response. Miraxion™ has been shown in Phase II clinical trials to benefit those individuals who do not respond to current anti-depressants. Amarin is listed on the NASDAQ small cap market under the symbol AMRN. The Company is headquartered in London, England, with a research and development facility in Stirling, Scotland.
|
